BGM
AVBP icon

Burkehill Global Management’s ArriVent BioPharma AVBP Stock Holding History

Burkehill Global Management’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.47M Hold
100,000
– – 0.13% 102
2026
Q1 		$2.31M Hold
100,000
– – 0.11% 117
2025
Q4 		$2.01M Hold
100,000
– – 0.13% 119
2025
Q3 		$1.84M Buy
+100,000
New +$1.96M 0.1% 123

Other funds holding AVBP

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Burkehill Global Management's AVBP Position: Q2 2026 in Review

Burkehill Global Management held its ArriVent BioPharma (AVBP) position steady in Q2 2026 at 100,000 shares worth $3.47M. The position accounts for 0.13% of the portfolio, ranked #102.

Burkehill Global Management first reported a position in AVBP in Q3 2025 and has held it in 4 quarters since. 158 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

  • Burkehill Global Management held 100,000 shares of ArriVent BioPharma worth $3.47M as of Q2 2026.
  • Burkehill Global Management left its ArriVent BioPharma share count unchanged in Q2 2026.
  • ArriVent BioPharma made up 0.13% of Burkehill Global Management's portfolio in Q2 2026, its #102 holding.
  • Burkehill Global Management first reported a position in ArriVent BioPharma in Q3 2025 and has held it in 4 quarters since.
  • 158 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on Burkehill Global Management's 13F filing for Q2 2026, filed 14 Aug 2026.